Tumor-targeted inhibition by a novel strategy - mimoretrovirus expressing siRNA targeting the Pokemon gene

Area of Science:

• Oncology
• Gene Therapy
• Nanomedicine

Background:

• Pokemon gene is a key regulator in cell differentiation, proliferation, and tumorigenesis, making it a promising cancer therapeutic target.
• Overexpression of Pokemon in various tumors highlights its role in cancer development and progression.
• Existing RNA interference (RNAi) strategies face challenges in tumor-specific delivery and sustained siRNA expression.

Purpose of the Study:

• To develop a targeted RNAi delivery system for silencing the Pokemon gene in cervical cancer.
• To evaluate the efficacy of a novel mimoretrovirus, combining RGD peptide and polylysine, for cancer therapy.
• To assess the anti-tumor capacity of the mimoretrovirus in vitro and in vivo.

Main Methods:

• Utilized an RNAi strategy to silence the Pokemon gene in a cervical cancer model.
• Developed a mimoretrovirus by encapsulating a recombinant retrovirus plasmid expressing Pokemon-targeting siRNA with RGD and K(18) fusion peptides.
• Characterized the nanoparticle formation, stability, and DNase I protection at a specific charge ratio (2.0).
• Investigated nanoparticle binding to SiHa cells via RGD-integrin α(v)β(3) interaction.
• Assessed in vitro effects on SiHa cell proliferation, invasion, and apoptosis.
• Evaluated in vivo anti-tumor efficacy in a nude mouse model.

Main Results:

• The mimoretrovirus formed stable, homogenous nanoparticles with complete DNase I protection and gel retardation at a charge ratio of 2.0.
• The nanoparticle significantly inhibited SiHa cell proliferation and invasion, while promoting apoptosis.
• RGD-mediated binding to SiHa cells was confirmed, with unconjugated RGD peptide inhibiting the interaction.
• The tumor-targeting mimoretrovirus demonstrated potent in vivo anti-tumor activity in a nude mouse model.
• The mimoretrovirus showed superior tumor growth inhibition compared to non-targeted retroviruses or nanoparticles lacking RGD.

Conclusions:

• The developed RNAi/RGD-based mimoretrovirus represents a novel and effective anti-tumor strategy.
• This targeted nanoparticle system shows promising potential for cervical cancer treatment.
• The mimoretrovirus platform may be applicable to various cancer therapies requiring targeted gene silencing.